Amylyx Pharmaceuticals, Inc.
Financials
Valuation Metrics
Amylyx Pharmaceuticals, Inc.'s Market Cap is $3.60B. At end of 2025 it was $1.14B. Ranked #1557 of 3,121 in US market (top 50%), #546 of 1,463 on NASDAQ (top 37%), #92 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.60B | US#1,557/3,121 Sec#92/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-152M | US—/3,121 Sec—/266 |
| Total Assets | $265M | US#2,945/3,121 Sec#222/266 |
| Net Assets | $239M | US#2,620/3,121 Sec#175/266 |
| Employees | 136 | US#2,575/3,121 Sec#156/266 |
| Value | ||
| P/B | 15.07x | US#2,744/3,121 Sec#210/266 |
| FCF Yield | -3.52% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -63.59% | US#2,731/3,121 Sec#179/266 |
| ROA | -57.49% | US#3,012/3,121 Sec#227/266 |
| Financial Health | ||
| Debt Ratio | 10.62% | US#119/3,121 Sec#53/266 |
| Total Debt | $5M | US#2,905/3,121 Sec#217/266 |
| FCF | $-127M | US#2,687/3,121 Sec#162/266 |
| Cash | $49M | US#2,582/3,121 Sec#226/266 |
| Current Ratio | 12.12x | US#209/3,121 Sec#64/266 |
| Performance | ||
| 1Y Return | 144.60% | US#91/3,121 Sec#37/266 |
| 1M Return | -16.04% | US#1,433/3,121 Sec#127/266 |
| From 52W High | -21.22% | US#1,316/3,121 Sec#92/266 |
| 1Y MDD | -30.61% | US#1,466/3,121 Sec#91/266 |
| Trading | ||
| Volume | 1,755,716 shares | US#1,087/3,121 Sec#111/266 |
| Trading Value | $58M | US#1,274/3,121 Sec#97/266 |
| Per Share | ||
| EPS | $-1.37 | US—/3,121 Sec—/266 |
| BPS | $2.15 | US#2,566/3,121 Sec#178/266 |
Company Info
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.